Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI I: Vedolizumab Induction and Maintenance in Ulcerative Colitis
NCT00783718Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jan 2009
- Primary completion
- Dec 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in ulcerative colitis (UC) (3 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Percentage of Participants With a Clinical Response at 6 weeks and Percentage of Participants in Clinical Remission at 52 weeks. Started Jan 2009; status: completed.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00783718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00783718.